Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $214.20 | Total: $1,071.00 |
| 1 | 10 | $181.44 | Total: $1,814.40 |
| 1 | 25 | $153.72 | Total: $3,843.00 |
| 1 | 50 | $131.04 | Total: $6,552.00 |
| 1 | 100 | $113.40 | Total: $11,340.01 |
Overview
Utomilumab (PF 05082566) is a humanized IgG2 antibody that targets the T-cell co-stimulatory receptor 4-1BBCD137 and acts as a 4-1BBCD137 agonist. It exhibits antitumor activity and may be used in the study of patients with advanced malignancies.
Chemical Properties
| Molecular Formula | C17H24N8O3 |
| Molecular Weight | 388.42 |
| CAS Numbers | 1417318-27-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
Storage and Handling
0C Short Term, -20C Long Term
References
Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BBCD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26[11] 2524-2534.